NEWS

04/23/2026

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaborat...

04/21/2026

Tempus to Report First Quarter 2026 Financial Results on May 5

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a...

04/15/2026

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-bra...

04/14/2026

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. “The research that Tempus is presenting at...

04/13/2026

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring...

04/09/2026

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal...

04/08/2026

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16. Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am...

04/01/2026

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate time to treatment. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results f...

03/25/2026

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology. Through this collaboration, Daiichi Sankyo will leverage Tempus’ proprietary foundation models and AI expert...

03/17/2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO, March 17, 2026 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehe...